Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: Synergistic action of estrogen metabolite and ligands of death receptor family

Cancer Research

Volumn 66, Issue 8, 2006, Pages 4309-4318

  Basu, Aruna ^a   Castle, Valerie P ^b   Bouziane, Mohammed ^c   Bhalla, Kapil ^d   Haldar, Subrata ^a,e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c BD BIOSCIENCES   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 8; CASPASE 9; CELL SURFACE RECEPTOR; DEATH RECEPTOR; DRUG METABOLITE; ESTROGEN; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 8; CASPASE 9; CASPASES; CELL LINE, TUMOR; DRUG SYNERGISM; ESTRADIOL; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTOR CROSS-TALK; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33646236326     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2657     Document Type: Article

References (56)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
3. Burke PA, DeNardo SJ. Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol 2001;39:155-71.
4. Qanungo S, Basu A, Das M, Haldar S. 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene 2002;21:4149-57.
5. Pribluda VS, Gubish ER, Jr., LaVallee TM, et al. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 2000;19:173-9.
6. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9.
7. Bergers G, Javaherian K, Lo K-M, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12.
8. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 1997;57:81-6.
9. LaVallee TM, Zhan XH, Herbstritt CJ, et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 2002;62:3691-7.
10. Yue T-L, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 1997;51:951-62.
11. MacCarthy-Morrogh L, Townsend PA, Purohit A, et al. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 2000;60:5441-50.
12. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000;407:390-5.
13. Tinley TL, Leal RM, Randall-Hlubek DA, et al. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res 2003;63:1538-49.
14. LaVallee TM, Zhan XH, Johnson MS, et al. 2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003;63:468-75.
15. Djavaheri-Mergny M, Wietzerbin J, Besancon F. 2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production. Oncogene 2003;22:2558-67.
16. Han GZ, Liu ZJ, Shimoi K, Zhu BT. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res 2005;65:387-93.
17. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
18. Zhu BT, Conney AH. Is 2-Methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998;58:2269-77.
19. Basu A, Haldar S. The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998;4:1099-109.
20. Wang X. The expanding role of mitochondria in apoptosis. Gene Dev 2001;15:2922-33.
21. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
22. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12.
23. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-9.
24. Chatfield K, Eastman A. Inhibitors of protein phosphatase 1 and 2A differentially prevent intrinsic and extrinsic pathways. Biochem Biophys Res Commun 2004;323:1313-20.
25. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.
26. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003;63:4713-23.
27. Bian X, Giordano TD, Lin HJ, et al. Chemotherapy-induced apoptosis of S-type neuroblastoma cells requires caspase-9 and is augmented by CD95/Fas stimulation. J Biol Chem 2004;279:4663-9.
28. Guo F, Sigua C, Tao J, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004;64:2580-9.
29. Singh TR, Shankar S, Chen X Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003;63:5390-400.
30. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004;95:777-83.
31. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003;14:337-48.
32. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 1998;58:1609-15.
33. Haldar S, Jena N, Croce CM. Inactivation of Bcl2 by phosphorylation. Proc Natl Acad Sci U S A 1995;92:4507-11.
34. Basu A, Haldar S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol-or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003;538:41-7.
35. Basu A, Das M, Qanungo S, et al. Proteasomal degradation of human peptidyl prolyl isomerase pin1-pointing phospho Bcl2 toward dephosphorylation. Neoplasia 2002;4:218-27.
36. Qanungo S, Das M, Haldar S, Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 2005;26:958-67.
37. Basu A, You SA, Haldar S. Regulation of Bcl2 phosphorylation by stress response kinase pathway. Int J Oncol 2000;16:497-500.
38. + efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3beta in prostate cancer cells. J Biol Chem 2002;277:17852-62.
39. Zhou P, Qian L, Bieszczad CK, et al. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998;92:3226-39.
40. Fearnhead HO, Rodriguez J, Govek EE, et al. Oncogene mediated apoptosis is mediated by caspase-9. Proc Natl Acad Sci U S A 1998;95:13664-9.
41. Chae Y-J, Kim H-S, Rhim H, et al. Activation of caspase-8 in 3-deazaadenosine-induced apoptosis of U-937 cells occurs downstream of caspase-3 and caspase-9 without Fas receptor-ligand interaction. Exp Mol Med 2001;33:284-92.
42. Viswanath V, Wu Y, Boonplueang R, et al. Caspase-9 activation results in downstream caspase-8 activation and Bid cleavage in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease. J Neurosci 2001;21:9519-28.
43. Hyer ML, Croxton R, Krajewska M, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of Breast Cancer Cells. Cancer Res 2005;65:4799-808.
44. Ikeda T, Sporn M, Honda T, Gribble GW, Kufe D. The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 2003;63:5551-8.
45. 2-terminal kinase-mediated upregulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 2004;64:7570-8.
46. Xia S, Rosen EM, Laterra J. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress. Cancer Res 2005;65:5248-55.
47. Li XR, Chong A, Wu J, et al. Transcriptional regulation of Fas gene expression by GA-binding protein and AP-1 in T cell antigen receptor CD3 complex-stimulated T cells. J Biol Chem 1999;274:35203-10.
48. Guan B, Yue P, Lotan R, Sun S-Y. Evidence that the death receptor 4 is regulated by activator protein 1. Oncogene 2002;21:3121-9.
49. Ueda S, Masutani H, Nakamura H, et al. Redox control of cell death. Antioxid Redox Signal 2002;4:405-14.
50. Izeradjene K, Douglas L, Tillman DM, Delaney AB, Houghton JA. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines. Cancer Res 2005;65:7436-45.
51. Thomas LR, Johnson RL, Reed JC, Thorburn A. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J Biol Chem 2004;279:52479-86.
52. Shimada K, Matsuyoshi S, Nakamura M, et al. Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis. Carcinogenesis 2004;25:1089-97.
53. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
54. Djavaheri-Mergny M, Wietzerbin J, Rouillard D, Besancon F. TNFalpha potentiates 2-methoxyestradiol-induced mitochondrial death pathway. Ann N Y Acad Sci 2003;1010:159-62.
55. Braeuninger S, Chamaon K, Kropf S, et al. Short incubation with 2-methoxyestradiol kills malignant glioma cells independent of death receptor 5 upregulation. Clin Neuropathol 2005;24:175-83.
56. Thomas RP, Farrow BJ, Kim S, et al. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery 2002;132:127-34.